No photo of Lakshmi Rajdev

View Scopus Profile

Lakshmi Rajdev, M.B.,B.S.

  • 588 Citations
  • 13 h-Index
20002019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Lakshmi Rajdev is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 26 Similar Profiles
Neoplasms Medicine & Life Sciences
gemcitabine Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
docetaxel Medicine & Life Sciences
Biliary Tract Neoplasms Medicine & Life Sciences
Survival Medicine & Life Sciences
Colorectal Neoplasms Medicine & Life Sciences
Immunotherapy Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Publications 2000 2019

  • 588 Citations
  • 13 h-Index
  • 29 Article
  • 4 Review article

Assessment of Treatment with Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients with Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial

Abou-Alfa, G. K., Shi, Q., Knox, J. J., Kaubisch, A., Niedzwiecki, D., Posey, J., Tan, B. R., Kavan, P., Goel, R., Lammers, P. E., Bekaii-Saab, T. S., Tam, V. C., Rajdev, L., Kelley, R. K., El Dika, I., Zemla, T., Potaracke, R. I., Balletti, J., El-Khoueiry, A. B., Harding, J. H. & 7 others, Suga, J. M., Schwartz, L. H., Goldberg, R. M., Bertagnolli, M. M., Meyerhardt, J., O'Reilly, E. M. & Venook, A. P., Jan 1 2019, (Accepted/In press) In : JAMA Oncology.

Research output: Contribution to journal › Article

Doxorubicin
Hepatocellular Carcinoma
Randomized Controlled Trials
Survival
Therapeutics

Comparing outcomes following total neoadjuvant therapy and following neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer

Zhu, S., Brodin, N. P., English, K., Ohri, N., Chuy, J. W., Rajdev, L. N., Narang, R., Kalnicki, S., Guha, C., Garg, M. K. & Kabarriti, R., Nov 2019, In : EClinicalMedicine. 16, p. 23-29 7 p.

Research output: Contribution to journal › Article

Open Access
Neoadjuvant Therapy
Rectal Neoplasms
Survival
Adjuvant Chemotherapy
Logistic Models

Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin

Rao, D., Mallick, A. B., Augustine, T., Daroqui, C., Jiffry, J., Merla, A., Chaudhary, I., Seetharam, R., Sood, A., Gajavelli, S., Aparo, S., Rajdev, L., Kaubisch, A., Chuy, J., Negassa, A., Mariadason, J. M., Maitra, R. & Goel, S., Jan 1 2019, In : Oncotarget. 10, 53, p. 5510-5522 13 p.

Research output: Contribution to journal › Article

oxaliplatin
DNA Repair
Colorectal Neoplasms
Disease-Free Survival
Single Nucleotide Polymorphism

Human papillomavirus, radiation dose and survival of patients with anal cancer

Kabarriti, R., Brodin, N. P., Ohri, N., Narang, R., Huang, R., Chuy, J. W., Rajdev, L. N., Kalnicki, S., Guha, C. & Garg, M. K., Jan 1 2019, In : Acta Oncologica.

Research output: Contribution to journal › Article

Anus Neoplasms
Radiation
Survival
Neoplasms
Propensity Score

Multimodality Management of Localized Biliary Cancer

Ashai, N., Prasad, P. & Rajdev, L., Jul 1 2019, In : Current Treatment Options in Oncology. 20, 7, 58.

Research output: Contribution to journal › Article

Biliary Tract Neoplasms
Drug Therapy
Neoadjuvant Therapy
Cholangiocarcinoma
Biliary Tract